
IMHOTEP, PJP, and more
May 14, 2026 - 00:09:59
Radio and PodcastLive Radio & Podcasts
Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it do...
Tazemetostat Withdrawl and RECITE is an episode from OncoPharm by OncoPharmPod. Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplat...
This episode belongs to OncoPharm.
Use the player on this page to stream the episode online.
Published Mar 19, 2026, 00:14:47 long, audio available.
Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter:
You can listen to Tazemetostat Withdrawl and RECITE online on Radio and Podcast. Open the player on this page to stream the available audio.
Tazemetostat Withdrawl and RECITE is an episode from OncoPharm by OncoPharmPod.
This episode is 00:14:47 long.
This episode was published on Mar 19, 2026.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from OncoPharm when more episodes are available from the podcast feed.